Related Experiment Videos

In vivo and in vitro genotoxic evaluation of indorenate

E Madrigal-Bujaidar1, E Rosas-Planaguma

  • 1Depto. de Morfología, Escuela Nacional de Ciencias Biológicas, I.P.N. Carpio y Plan de Ayala, Mexico, D.F.

Mutation Research
|April 1, 1989
PubMed

Insights

Indorenate, a novel antihypertensive drug, was assessed for genotoxicity. Both mouse and human cell assays confirmed that indorenate does not cause genetic damage.

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • 5-Methoxytryptamine, beta-methylcarboxylate hydrochloride (indorenate) is a novel serotonin derivative developed for antihypertensive applications.
  • Assessing the genotoxic potential of new pharmaceutical agents is crucial for drug safety and regulatory approval.

Purpose of the Study:

  • To evaluate the genotoxic activity of indorenate using established in vitro and in vivo cytogenetic assays.
  • To determine if indorenate induces chromosomal aberrations, sister-chromatid exchanges, or affects cellular proliferation kinetics.

Main Methods:

  • The study employed a mouse bone marrow cytogenetic test to assess in vivo genotoxicity.
  • Human lymphocyte cultures were utilized for an in vitro cytogenetic assay.
  • Key endpoints measured included chromosomal aberrations, sister-chromatid exchanges, and cellular proliferation kinetics.

Main Results:

  • Consistent results were observed across both the mouse bone marrow and human lymphocyte assays.
  • Indorenate did not induce a significant increase in chromosomal aberrations in either test system.
  • No evidence of genotoxicity, including sister-chromatid exchanges or altered proliferation kinetics, was found for indorenate.

Conclusions:

  • Indorenate demonstrates a lack of genotoxic activity in the evaluated mouse and human cell systems.
  • These findings suggest that indorenate is a non-genotoxic agent, supporting its further development as an antihypertensive medication.

Related Concept Videos